Loi and colleagues analyzed biopsy specimen from 156 patients with HER-2/neu positive breast cancer enrolled in GeparQuatro trial and treated with trastuzumab containing neoadjuvant chemotherapy [15]. The gene discussed is ERBB2; the disease is breast carcinoma.